Do not administer VERQUVO® (vericiguat) to a pregnant female because it may cause fetal harm and is contraindicated during pregnancy. Advise females of reproductive potential to use effective contraception during treatment and for one month after the final dose. Healthcare Providers should report any prenatal exposure to VERQUVO by calling 1-877-888-4231 or by filling out the form below.
Healthcare Providers in the United States (U.S.) should report an exposure to VERQUVO during pregnancy by:
Contacting Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. at 1-877-888-4231
Entering contact information below to receive a callback within 1 business day to provide information regarding the pregnancy exposure.
Healthcare Providers outside of the U.S., should contact their local MSD office.
* Fields marked with an asterisk are required to be completed to receive a callback.
For other inquiries, please contact Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. at 1-800-672-6372
Please provide your name and phone number:
Please provide your patient’s name and contact phone number:
To report an adverse event or product quality complaint in the U.S., please contact the company at 1-800-672-6372. If you are outside the U.S., please contact your local MSD office.